Asthma

Airsupra (albuterol/budesonide) has been approved in the US for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in people with asthma aged 18 years and older.  Airsupra is a pressurised metered-dose inhaler (pMDI), fixed-dose combination of albuterol, a short-acting beta2-agonist (SABA), and budesonide, an anti-inflammatory inhaled corticosteroid (ICS). It […]

AstraZeneca’s Tezspire (tezepelumab) has been approved in the European Union as an add-on maintenance treatment in patients 12 years and older with severe asthma who are inadequately controlled with high dose inhaled corticosteroids plus another medicinal product.  The approval by the European Commission was based on results from the Pathfinder clinical trial programme, which included […]

Pharmaceutical company Transpire Bio will work alongside drug delivery provider Recipharm to develop two inhaled medicines for the treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD).   Transpire Bio announced a definitive agreement with Recipharm to develop its TRB-1 and TRB-2 inhaled medicines. These are the first products developed by Transpire Bio and will be […]

New results from an observational data analysis of asthma inhaler therapy found that short-acting beta2-agonist (SABA) reliever overuse is a global issue adversely impacting asthma outcomes.1,2   Data from across the SABA Use IN Asthma (SABINA) global programme have been published in The Journal of Allergy and Clinical Immunology: In Practice (JACI: In Practice) and the […]

Results from a pooled post-hoc analysis of the pivotal NAVIGATOR Phase III and PATHWAY Phase IIb trials showed AstraZeneca and Amgen’s Tezspire (tezepelumab) demonstrated reductions in the annualised asthma exacerbation rate (AAER) across biomarker subgroups of patients with severe asthma.1 According to the company, these findings support the role of Tezspire as a first-in-class treatment […]